SEC Form 4 · accession 0001209191-17-027776
aTYR PHARMA INC · LIFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Mendlein
Officer — CEO and Director · Director
Period of report
Apr 18, 2017
Accepted (ET)
Apr 20, 2017 · 7:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339970
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 18, 2017 | P | 1,000 | $3.00 | A | 325,971 | D | |
| Common Stock | Apr 20, 2017 | P | 1,552 | $3.00 | A | 327,523 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 21, 2016.